Physician profile
Yvonne R Stumpf
NPI 1679586150
$1,038.64
in general payments reported to CMS, 2019-2025
13 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Psychiatric/Mental Health, Child & Adolescent (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $315).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $341 · 2024: $156 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $485.11 | 2023-2025 | Quillivant, Quillichew Er, Dyanavel Xr |
| Corium, LLC | $200.36 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $121.35 | 2023 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.05 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $31.39 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $29.35 | 2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $25.54 | 2023 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $23.77 | 2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $20.80 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $19.79 | 2024 | Rexulti |
| Neos Therapeutics, Lp | $17.79 | 2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $16.06 | 2025 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $14.28 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvonne Stumpf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.